40,993 Shares in Harmony Biosciences Holdings, Inc. $HRMY Acquired by Ruffer LLP

Ruffer LLP purchased a new position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 40,993 shares of the company’s stock, valued at approximately $1,536,000.

Other large investors have also bought and sold shares of the company. Public Sector Pension Investment Board grew its position in Harmony Biosciences by 41.6% during the 3rd quarter. Public Sector Pension Investment Board now owns 185,803 shares of the company’s stock worth $5,121,000 after acquiring an additional 54,605 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH grew its position in Harmony Biosciences by 39.3% during the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 234,779 shares of the company’s stock worth $6,471,000 after acquiring an additional 66,236 shares during the last quarter. Exchange Traded Concepts LLC boosted its position in Harmony Biosciences by 102.6% in the 3rd quarter. Exchange Traded Concepts LLC now owns 65,023 shares of the company’s stock valued at $1,792,000 after buying an additional 32,923 shares during the last quarter. American Century Companies Inc. boosted its position in Harmony Biosciences by 11.2% in the 3rd quarter. American Century Companies Inc. now owns 1,669,565 shares of the company’s stock valued at $46,013,000 after buying an additional 168,145 shares during the last quarter. Finally, LSV Asset Management boosted its position in Harmony Biosciences by 7.1% in the 3rd quarter. LSV Asset Management now owns 1,594,893 shares of the company’s stock valued at $43,955,000 after buying an additional 106,391 shares during the last quarter. 86.23% of the stock is currently owned by institutional investors.

Harmony Biosciences Stock Down 0.5%

Shares of HRMY opened at $31.97 on Thursday. The business’s fifty day moving average price is $29.30 and its two-hundred day moving average price is $32.68. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.58 and a current ratio of 3.60. The firm has a market capitalization of $1.85 billion, a price-to-earnings ratio of 11.80, a PEG ratio of 0.44 and a beta of 0.89. Harmony Biosciences Holdings, Inc. has a 52 week low of $25.52 and a 52 week high of $40.87.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $0.38 earnings per share for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.46). The company had revenue of $243.78 million during the quarter, compared to analyst estimates of $240.04 million. Harmony Biosciences had a net margin of 18.29% and a return on equity of 19.86%. The business’s revenue for the quarter was up 21.1% compared to the same quarter last year. During the same period last year, the company earned $0.85 EPS. On average, analysts predict that Harmony Biosciences Holdings, Inc. will post 3.33 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on HRMY shares. Needham & Company LLC decreased their price objective on Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. UBS Group decreased their price objective on Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. Truist Financial lowered Harmony Biosciences from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Weiss Ratings reiterated a “hold (c)” rating on shares of Harmony Biosciences in a research report on Monday, December 29th. Finally, Zacks Research lowered Harmony Biosciences from a “hold” rating to a “strong sell” rating in a research report on Thursday, March 26th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Harmony Biosciences presently has an average rating of “Hold” and an average price target of $42.67.

Insider Buying and Selling at Harmony Biosciences

In other news, CFO Sandip Kapadia sold 3,746 shares of the stock in a transaction on Monday, January 26th. The stock was sold at an average price of $37.15, for a total value of $139,163.90. Following the transaction, the chief financial officer owned 24,521 shares of the company’s stock, valued at $910,955.15. This represents a 13.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 11.00% of the stock is currently owned by company insiders.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.